webinar register page

Webinar banner
Leveraging Single-Cell Multi-Omic Analytical Assays to Accelerate Advanced Therapeutics Development


May 25, 2021 09:08 AM

Webinar logo
* Required information


Matt Cato
Director, Cell and Gene Therapy @Mission Bio
Matthew Cato is a business and market development leader who specializes in cell and gene therapies and precision medicine. With a background in immunology and biotechnology, he focuses on strategic commercial development for single-cell technology to advance cell and gene therapeutic solutions.
Jenny Xiao
Associate Director, Emerging Technologies @Illumina
Jenny Xiao is Associate Director, Emerging Market, for NGS genomic applications at Illumina. She currently focuses on developing KOL relationships and scientific society engagements in the field of Gene editing, Single cell, Spatial, and Proteomics. Examples include participating NIST (National institute of standard and technology) genome editing consortium to develop standard control samples and off-target validation procedure for gene editing based cell and gene therapies. Jenny completed her BS in Biology at Peking University, MBA at Santa Clara University and Ph.D. in Entomology at University of Hawaii at Manoa. After her postdoctoral training at Stanford Medical School, Jenny held different technical and commercial roles at Agilent Technologies, Agena, and Thermo Fisher Scientific with leading genomic technologies, including microarray, Mass-spec, real-time PCR, Sanger Sequencing, and NGS. She has worked with researchers in the field of molecular diagnostics, agricultural biotech